These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Therapy with renin-angiotensin system blockers after pulmonary vein isolation in patients with atrial fibrillation: who is a responder? Berkowitsch A; Neumann T; Kuniss M; Janin S; Wojcik M; Zaltsberg S; Mitrovic V; Pitschner HF Pacing Clin Electrophysiol; 2010 Sep; 33(9):1101-11. PubMed ID: 20487340 [TBL] [Abstract][Full Text] [Related]
45. New treatment strategies in patients with impaired left ventricular systolic function. Part II: Treatment of moderate to severe cardiac dysfunction. Rozo JC; Barry WL; Stouffer GA Am J Med Sci; 1999 May; 317(5):312-7. PubMed ID: 10334119 [No Abstract] [Full Text] [Related]
46. Right ventricular outflow tract obstruction in hypertrophic cardiomyopathy. Recupero A; Di Bella G; Patanè S; Pugliatti P; Tripodo E; Carerj S; Coglitore S Int J Cardiol; 2010 Oct; 144(3):e56-7. PubMed ID: 19167104 [TBL] [Abstract][Full Text] [Related]
47. [Arrhythmia risk stratification in patients with heart failure according to drug treatment and its effects]. Gronda E; Mangiavacchi M; Andreuzzi B; Municinò A Ital Heart J Suppl; 2001 Dec; 2(12):1278-83. PubMed ID: 11838348 [TBL] [Abstract][Full Text] [Related]
48. [Practical aspects of diagnosis, treatment and prognosis in chronic heart failure]. Wagdi P Dtsch Med Wochenschr; 1999 Mar; 124(10):291-5. PubMed ID: 10191824 [No Abstract] [Full Text] [Related]
49. Paradoxical response to exercise in asymptomatic hypertrophic cardiomyopathy: a new description of outflow tract obstruction dynamics. Lafitte S; Reant P; Touche C; Pillois X; Dijos M; Arsac F; Peyrou J; Montaudon M; Ritter P; Roudaut R; Demaria A J Am Coll Cardiol; 2013 Aug; 62(9):842-50. PubMed ID: 23810875 [TBL] [Abstract][Full Text] [Related]
50. New perspectives in the pharmacological treatment of hypertrophic cardiomyopathy. Maltês S; Lopes LR Rev Port Cardiol (Engl Ed); 2020 Feb; 39(2):99-109. PubMed ID: 32245685 [TBL] [Abstract][Full Text] [Related]
51. A systems BIOlogy Study to TAilored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF. Voors AA; Anker SD; Cleland JG; Dickstein K; Filippatos G; van der Harst P; Hillege HL; Lang CC; Ter Maaten JM; Ng L; Ponikowski P; Samani NJ; van Veldhuisen DJ; Zannad F; Zwinderman AH; Metra M Eur J Heart Fail; 2016 Jun; 18(6):716-26. PubMed ID: 27126231 [TBL] [Abstract][Full Text] [Related]
52. Newer drug therapy for congestive heart failure. Coodley E Arch Intern Med; 1999 Jun; 159(11):1177-83. PubMed ID: 10371225 [TBL] [Abstract][Full Text] [Related]
53. Effect of atenolol on heart rate, arrhythmias, blood pressure, and dynamic left ventricular outflow tract obstruction in cats with subclinical hypertrophic cardiomyopathy. Jackson BL; Adin DB; Lehmkuhl LB J Vet Cardiol; 2015 Dec; 17 Suppl 1():S296-305. PubMed ID: 26776587 [TBL] [Abstract][Full Text] [Related]
54. [Therapeutic measures following acute myocardial infarct: differential use of PTCA, surgery and drugs]. Noll G; Kaufmann U; Wenzel RR; Lüscher TF Schweiz Med Wochenschr; 1996 Feb; 126(5):164-76. PubMed ID: 8685687 [TBL] [Abstract][Full Text] [Related]
55. Novel Approach Targeting the Complex Pathophysiology of Hypertrophic Cardiomyopathy: The Impact of Late Sodium Current Inhibition on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy (LIBERTY-HCM) Trial. Olivotto I; Hellawell JL; Farzaneh-Far R; Blair C; Coppini R; Myers J; Belardinelli L; Maron MS Circ Heart Fail; 2016 Mar; 9(3):e002764. PubMed ID: 26915375 [TBL] [Abstract][Full Text] [Related]
56. [Hypertrophic obstructive cardiomyopathy: current treatment, indications and results]. Delahaye JP; Azzano O Presse Med; 1994 May; 23(20):925-7. PubMed ID: 7937627 [TBL] [Abstract][Full Text] [Related]
57. Clinical characteristics and long-term prognosis in patients with chronic heart failure and reduced ejection fraction in China. Liu X; Yu H; Pei J; Chu J; Pu J; Zhang S Heart Lung Circ; 2014 Sep; 23(9):818-26. PubMed ID: 24881031 [TBL] [Abstract][Full Text] [Related]
58. Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions. Dong T; Alencherry B; Ospina S; Desai MY Drug Des Devel Ther; 2023; 17():1097-1106. PubMed ID: 37064432 [TBL] [Abstract][Full Text] [Related]
59. Management of hypertrophic cardiomyopathy. Enriquez AD; Goldman ME Ann Glob Health; 2014; 80(1):35-45. PubMed ID: 24751563 [TBL] [Abstract][Full Text] [Related]
60. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005]. Fabbri G; Gorini M; Maggioni AP; Di Lenarda A; G Ital Cardiol (Rome); 2007 Feb; 8(2):102-6. PubMed ID: 17402354 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]